Login to Your Account

AACR 2012

Nanoparticle Shows Preclinical Promise, Early Clinical Success

By Anette Breindl
Science Editor

Thursday, April 5, 2012
Scientists from BIND Biosciences Inc., with colleagues from both academia and industry, reported data Wednesday on a targeted therapy, BIND-014, that is able to specifically deliver chemotherapy docetaxel to prostate tumor cells and the vasculature of many different types of solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription